San Carlos, CA, United States
San Carlos, CA, United States

Time filter

Source Type

News Article | May 11, 2017
Site: www.businesswire.com

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC, (PPD) today announced it recently has added two new leaders in product development, strengthening the global contract research organization’s therapeutic expertise and ability to aid biopharmaceutical clients in delivering life-changing therapies to patients. “PPD’s global team of scientific, medical and strategic experts provides our clients expertise that helps reduce the cost and time associated with bringing medicines to market,” said Rob Dow, senior vice president of medical affairs for PPD. “By joining this team, these leaders deepen our expertise in neuroscience, pediatrics and rare diseases – areas that are very important to PPD and our customers.” Stephen Peroutka, M.D., Ph.D., has joined PPD to serve as vice president of global product development and therapeutic area head for neuroscience. Peroutka has served as an advisor and consultant to several biopharmaceutical companies. He previously served as chief medical officer at Semnur Pharmaceuticals and as chief medical officer and executive vice president of NeurogesX Inc. Earlier, he served as vice president of neurosciences for a large contract research organization (CRO); chief medical officer of Zogenix Inc.; franchise leader for pain conditions at Johnson & Johnson Inc.; founder, CEO and president of Synergia Pharma Inc.; and founder, CEO and president of Spectra Biomedical Inc., a startup focused on identification of genes in migraine, later acquired by GSK. Peroutka served as chief of the neurology service at the Palo Alto Veteran’s Administration Hospital. He earned both a medical and doctoral degree in pharmacology and experimental therapeutics from Johns Hopkins University School of Medicine. Horacio Plotkin, M.D., FAAP, joined PPD as vice president of global product development in the pediatrics and rare diseases therapeutic area and also serves as medical lead for the Rare Disease and Pediatric Center of Excellence. Plotkin most recently served as global clinical development lead at Shire. Previously, he spent three years as chief medical officer of Retrophin, Inc., and held medical director positions at Alexion Pharmaceuticals, Enobia Pharma and Genzyme Corp. He spent 20 years as a practicing pediatrician in the field of pediatric rare diseases. Plotkin serves as adjunct associate professor of pediatrics and orthopedic surgery at the University of Nebraska School of Medicine. He earned his medical degree from the University of Buenos Aires School of Medicine. PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 19,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com. Any statements made in this news release that are not statements of historical fact, including statements about the future performance of personnel, are forward-looking statements that involve a number of risks and uncertainties. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “might,” “will,” “forecast” and other similar expressions. The forward-looking statements contained in this news release are subject to and involve risks, uncertainties and assumptions, and therefore you should not place undue reliance on them. Although PPD believes these forward-looking statements are based on reasonable assumptions at the time they are made, many factors are beyond PPD’s ability to control or predict and could affect the outcome of the subject matter of this news release and our actual financial results, and therefore the outcome and results might differ materially from those expressed in the forward-looking statements. Additional factors that might materially affect the forward-looking statements include, but are not limited to: our ability to recruit, retain and motivate key personnel; the competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; rapid technological changes that make our services less competitive or obsolete; the impacts of political, economic and/or regulatory changes on the health care industry; the fact that our backlog may not accurately predict or convert into service revenue; the termination, delay or change in scope of our contracts; industry, customer or therapeutic concentration; the pricing of and cost management of customer contracts; information and communication systems failures; contractual failures; regulatory and ethical standards failures; our ability to attract investigators and enroll patients in clinical trials; violations of laws governing privacy, conduct of clinical trials and/or other pharmaceutical research; competition between existing and potential customers; management of business restructurings and acquisitions; risk relating to the performance of drug development services and our insurance coverages, if any, for such risks; U.S. or international economic, currency, political and other risks; changes in existing or interpretations of tax laws; factors impacting the value of our goodwill and intangible assets; and other factors. PPD assumes no obligation and expressly disclaims any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. PPD is not responsible for updating the information contained in this news release beyond the published date, or for changes made to this news release by wire services or internet service providers or any other party.


News Article | May 12, 2017
Site: globenewswire.com

Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report to their offering. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline. Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch. Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report highlights: - Introduction & Classification of Transdermal Patch - Mechanism of Transdermal Patch Drug Delivery - Transdermal Patch v/s Traditional Drug Delivery Methods - Global Transdermal Patch Clinical Pipeline Overview - Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase - Global Transdermal Patch Market Future Prospects Key Topics Covered: 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch 5. Transdermal Patch v/s Traditional Drug Delivery Methods 6. Global Transdermal Patch Market Outlook 6.1 Global Market Scenario 6.2 Regional Trends 7. Global Transdermal Patch Clinical Pipeline Overview 7.1 By Phase 7.2 By Region/Country 7.3 By Drug Class/Molecule 7.4 By Company 7.5 By Orphan & Fast Track Status 7.6 By Mode of Action 8. Global Transdermal Patch Market Dynamics 8.1 Favorable Market Parameters 8.2 Commercialization Challenges 9. Global Transdermal Patch Market Future Prospects 10. Global Transdermal Patch Clinical Insight 10.1 Unknown 10.2 Research 10.3 Preclinical 10.4 Clinical 10.5 Phase-I 10.6 Phase-I/II 10.7 Phase-II 10.8 Phase-II/III 10.9 Phase-III 10.10 Preregistration 10.11 Registered 11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase 12. Competitive Landscape 12.1 3M Pharmaceuticals 12.2 Acrux 12.3 Agile Therapeutics 12.4 Allergan 12.5 ANI Pharmaceuticals 12.6 Antares Pharma 12.7 Bayer HealthCare Pharmaceuticals 12.8 Corium International 12.9 Chase Pharmaceuticals 12.10 DURECT Corporation 12.11 Endo Pharmaceuticals 12.12 Fempharm 12.13 Hisamitsu Pharmaceutical 12.14 Immune Pharmaceuticals 12.15 Imprimis Pharmaceuticals 12.16 Ipsen Bioscience 12.17 Johnson & Johnson 12.18 LaSalle Laboratories 12.19 Lavipharm-increase 12.20 MINRAD International 12.21 NeurogesX 12.22 Noven Pharmaceuticals 12.23 NuPathe 12.24 Nuvo Research 12.25 Novartis 12.26 Pain Therapeutics 12.27 ProStrakan 12.28 Purdue Pharma 12.29 Sanofi 12.30 Scilex Pharmaceuticals 12.31 Senju Pharmaceutical 12.32 Somerset Pharmaceuticals 12.33 Teikoku Seiyaku 12.34 Therapeutic Discovery Corporation 12.35 Transdermal Delivery Solutions Corp 12.36 UCB-full form 12.37 Xel Pharmaceuticals 12.38 Zosano Pharma For more information about this report visit http://www.researchandmarkets.com/research/d2p9zx/global


News Article | May 12, 2017
Site: globenewswire.com

Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report to their offering. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline. Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch. Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report highlights: - Introduction & Classification of Transdermal Patch - Mechanism of Transdermal Patch Drug Delivery - Transdermal Patch v/s Traditional Drug Delivery Methods - Global Transdermal Patch Clinical Pipeline Overview - Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase - Global Transdermal Patch Market Future Prospects Key Topics Covered: 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch 5. Transdermal Patch v/s Traditional Drug Delivery Methods 6. Global Transdermal Patch Market Outlook 6.1 Global Market Scenario 6.2 Regional Trends 7. Global Transdermal Patch Clinical Pipeline Overview 7.1 By Phase 7.2 By Region/Country 7.3 By Drug Class/Molecule 7.4 By Company 7.5 By Orphan & Fast Track Status 7.6 By Mode of Action 8. Global Transdermal Patch Market Dynamics 8.1 Favorable Market Parameters 8.2 Commercialization Challenges 9. Global Transdermal Patch Market Future Prospects 10. Global Transdermal Patch Clinical Insight 10.1 Unknown 10.2 Research 10.3 Preclinical 10.4 Clinical 10.5 Phase-I 10.6 Phase-I/II 10.7 Phase-II 10.8 Phase-II/III 10.9 Phase-III 10.10 Preregistration 10.11 Registered 11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase 12. Competitive Landscape 12.1 3M Pharmaceuticals 12.2 Acrux 12.3 Agile Therapeutics 12.4 Allergan 12.5 ANI Pharmaceuticals 12.6 Antares Pharma 12.7 Bayer HealthCare Pharmaceuticals 12.8 Corium International 12.9 Chase Pharmaceuticals 12.10 DURECT Corporation 12.11 Endo Pharmaceuticals 12.12 Fempharm 12.13 Hisamitsu Pharmaceutical 12.14 Immune Pharmaceuticals 12.15 Imprimis Pharmaceuticals 12.16 Ipsen Bioscience 12.17 Johnson & Johnson 12.18 LaSalle Laboratories 12.19 Lavipharm-increase 12.20 MINRAD International 12.21 NeurogesX 12.22 Noven Pharmaceuticals 12.23 NuPathe 12.24 Nuvo Research 12.25 Novartis 12.26 Pain Therapeutics 12.27 ProStrakan 12.28 Purdue Pharma 12.29 Sanofi 12.30 Scilex Pharmaceuticals 12.31 Senju Pharmaceutical 12.32 Somerset Pharmaceuticals 12.33 Teikoku Seiyaku 12.34 Therapeutic Discovery Corporation 12.35 Transdermal Delivery Solutions Corp 12.36 UCB-full form 12.37 Xel Pharmaceuticals 12.38 Zosano Pharma For more information about this report visit http://www.researchandmarkets.com/research/d2p9zx/global

Loading NeurogesX collaborators
Loading NeurogesX collaborators